Bengt Erik Haug
Bengt Erik is CSO of KinSea Lead Discovery. He is a synthetic organic chemist by training and has more than 20 years of experience in medicinal chemistry, small molecule synthesis, and early-stage drug discovery.
Bengt Erik received his PhD in chemistry from the University of Tromsø, Norway in 2002. He did a postdoc at the School of Pharmacy at the University of Wisconsin, Madison, USA, before joining Lytix Biopharma in Tromsø, where played a key role in the discovery of first-in-class clinical candidate LTX-315.
In 2007, he joined the University of Bergen where he is professor of medicinal chemistry at the Department of Chemistry and the Centre for Pharmacy.